Next Up

Immuno 2024

25 - 26 April 2024 |

London, UK

25 - 26 April 2024

London, UK

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions o n different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

07 Dec 2023
Thu, 07 December 2023

Uncovering Mechanisms of Immunotherapy Response and Resistance with Single Cell and Spatial Multiomics Webinar

Presented by Abbey Cutchin, Associate Director, Oncology Marketing, 10x Genomics

Oct 2024
October 2024

Immuno US 2024

Highlights

Angelica Loskog, CEO, Lokon Pharma (featured)
Industry Spotlight
Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.
Edited by Tom Cohen |
14 November 2023
Therapeutic Modalities
Industry Spotlight
Edited by Tom Cohen |
07 Nov 2023
Tumour Microenvironment

In-Depth

Insight Article
Unpacking the potential of combining immuno-oncology and chemotherapy: understanding benefits, real-world impact, and addressing concerns.
18 September 2023
Insight Article
Sourcing NK cells, expansion techniques, gene modification, quality control, safety, preservation, and delivery.
22 August 2023
Insight Article
The importance of validating hypotheses, understanding the biology of cancer progression, and utilising biomarkers in early screening to stratify populations and improve clinical endpoints.
14 August 2023
Insight Article
Unveiling advancements in preclinical immuno-oncology: Exploring humanized mouse models and human knock-in mice for targeted cancer therapies.
02 August 2023

Industry Spotlight

Industry Spotlight
Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.
14 November 2023
Industry Spotlight
Explore the cutting-edge of oncolytic virus immunotherapy in immuno-oncology: the viruses revolutionizing cancer treatment and the promise they hold for future therapies.
14 November 2023
Industry Spotlight
Compugen's candidate therapeutic, COM503, targets interleukin-18 binding protein to unleash interleukin-18's immunostimulatory power.
13 November 2023
Industry Spotlight
TILT-123, an oncolytic virotherapy, has shown promising results from a phase I clinical trial which treats solid tumours in patients that have exhausted other options.
07 November 2023

[sponsor section - bespoke content]

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno